Skip to main content
Premium Trial:

Request an Annual Quote

Clarient to Sell CombiMatrix's DNAarray Products

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CombiMatrix today said that Clarient has licensed rights to commercialize its DNAarray product portfolio.

The tests are based on array comparative genomic hybridization, and according to CombiMatrix, can provide physicians with "a comprehensive genomic profile of solid cancer tumors and blood-based cancers," which can help guide treatment.

The agreement provides Clarient, which is owned by GE Healthcare, with exclusive rights to commercialize oncology-related tests among commercial laboratories, based on certain minimum levels of sales. Financial and other terms of the deal were not disclosed.

"Our new collaboration calls for cooperative sales and marketing between our companies and also allows for an active relationship between the medical and scientific teams, which over time we believe will help to drive both the commercial adoption of DNAarray testing and the development of new companion diagnostics in the oncology space," R. Judd Jessup, president and CEO of Irvine, Calif.-based CombiMatrix, said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more